Biohaven celebrates PhII/III win for intranasal CGRP migraine drug amid oral race with Allergan
In the run-up to an FDA decision on its migraine pill, Biohaven is brandishing a second weapon from its CGRP arsenal — an intranasal formulation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
